You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Clinical features of patients infected or colonized with MRCoNS with reduced susceptibility to glycopeptides

From: Investigation of Staphylococcus strains with heterogeneous resistance to glycopeptides in a Turkish university hospital

Patients Strain No Age/sex Ward Clinical feature Underlying disease Specimen Duration of hospitalization (days) Previous treatment with glycopeptide (days) Treatment with glycopeptide (days) Clinical outcome
4504 46/F Infectious Diseases Pneumonia Trauma tracheal aspiration fluid 20 No vancomycin (14) Improved
4505 33/M Haematology Septicemia CML Groin skin 27 No No NT
4506 44/M Haematology Septicemia AML Abdominal wall skin 46 vancomycin (20) No NT
4507 46/F Haematology Septicemia ALL Axilla skin 60 vancomycin (10) No NT
4508 26/M SICU Septicemia Trauma and Fracures Of mandibula and maxilla Blood 31 No vancomycin (10) Improved
4510 75/F Infectious Diseases Septicemia Surgical operation of Colon Blood 6 No vancomycin (14) Death not related to staphylococcal infection
  1. Abbreviations: M, male; F, female; CML, chronic myelogenous leukemia; AML, acute myelogenous leukemia; AML, acute lymphocytic leukemia; SICU, surgical intensive care unit; NT, staphylococci skin colonization not treated.